Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin Glargine (Lantus) Clear all
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

NCT00596687
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient Hyperglycemia
Interventions
Insulin glargine, Regular insulin, Insulin glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

NCT00851903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 71 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lantus in Prediabetes

NCT00348972
View directory record Official record
Conditions
Hyperglycemia, Diabetes Mellitus
Interventions
Lantus® (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2006 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

NCT01658579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Temecula, California • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Results available

Characteristics of Glargine in Type 2 Diabetics

NCT00574912
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

NCT01959529
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
7,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
267
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT02273180
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, Humalog, Insulin glargine HOE901
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional

Lantus in the Treatment of Type 1 Diabetes Children

NCT00206401
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Lantus and short acting analogs Vs NPH and short acting analogs
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

NCT02152371
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide, Placebo, Insulin Glargine, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Fresno, California • San Mateo, California • Tustin, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

NCT00838916
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, insulin glargine
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
314
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

NCT01107717
View directory record Official record
Conditions
Diabetes
Interventions
metformin\pioglitazone\exenatide, metformin, glyburide and glargine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

NCT03260868
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04460885
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Liraglutide Hospital Discharge Trial

NCT01919489
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Liraglutide + OADs, Glargine + OADs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

NCT01196104
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

NCT02735044
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 1, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

NCT00670228
View directory record Official record
Conditions
AMI
Interventions
Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01068665
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
62
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 1 Diabetes Mellitus

NCT01481779
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glargine, LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Concord, California • Escondido, California • Fresno, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 1, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

NCT01226043
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 1, 2026, 10:24 PM EDT